Talking Euretina

In tertiary practice, masquerades account for around 5% of uveitis cases — and missing one can cost sight, or life. Prof Bahram Bodaghi is joined by Prof Elisabetta Miserocchi and Prof Isabelle Audo on vitreoretinal lymphoma, the limits of diagnostic vitrectomy, IL-10:IL-6 ratios and MYD88, the paraneoplastic retinopathies CAR, MAR and BDUMP, and the inherited retinal diseases that quietly mimic inflammation. Essential listening before reaching for steroids

The Euretina Innovation Spotlight returns to Vienna on 30 September, bringing clinicians, industry, investors and regulators around one table. Prof. Anat Loewenstein, Prof. Nicole Eter and Dr. Kourous Rezaei tell Jonathan McCrea why innovation in retina is moving faster than ever, what the return of the EMA's Jane Mosley means for bridging Europe and the US, and why this exchange of ideas is something a traditional congress simply can't offer

Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.

A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Dr Emine Kiliç chairs a multidisciplinary discussion with Dr Iwona Rospond-Kubiak (Poznań), Prof. Antonia Joussen (Charité, Berlin) and radiation oncologist Dr Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.

Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what's new and why participation from the whole community - women and men alike - is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.